Henry Schein (HSIC) Q2 2026 Earnings Call Transcript
Henry Schein (HSIC) reported Q2 2026 net sales of $3.5 billion, up 6.7%, and non-GAAP diluted EPS of $1.27. GAAP diluted EPS was $0.82. The company raised 2026 guidance, including non-GAAP EPS to $5.29 to $5.39 and sales growth to 4.5% to 5.5%, and approved $200 million in share repurchases.
How this was made
The 30-second read
Why it matters
Management reported 6.7% total net sales growth, expanded non-GAAP operating margin, and raised FY 2026 guidance while reiterating a multiyear $200 million operating income improvement program.
Market read
Traders can update FY 2026 earnings models using the raised EPS and sales guidance, and monitor whether Q3 and Q4 are the key inflection points for the $200 million value-creation plan.
What to watch
U.S. medical distribution growth is noted despite headwinds in point-of-care diagnostic products, which could cap upside if respiratory diagnostics weakness persists.
Background
The article is a transcript-style summary of Henry Schein’s Q2 2026 earnings call, including financial results, guidance, and strategic initiatives.
Ticker impact
Henry Schein raised full-year 2026 non-GAAP EPS guidance to $5.29 to $5.39 and sales growth to 4.5% to 5.5% on the Q2 call.
Moderately positive bias for the next few sessions as traders reprice FY 2026 EPS and margin trajectory.
The article discloses specific, time-relevant guidance ranges, margin metrics, and a multiyear operating income improvement plan, which typically drives estimate revisions.
Market effects
Dental distribution and practice-management software peers may see read-across on demand durability and margin expansion from proprietary brands and cloud platforms.
International dental merchandise growth highlighted strength in Canada and France, which could influence regional demand expectations for distributors.
Global technology sales growth tied to cloud-based software momentum may reinforce investor focus on recurring software mix in healthcare distribution.
Counterpoint
Value-creation benefits are described as timing-weighted toward Q3 and Q4, so near-term execution risk could limit how quickly margins translate into earnings.
Key entities
- companyHenry Schein, Inc.
Reported Q2 2026 results and raised FY 2026 non-GAAP EPS and sales growth guidance; outlined value-creation initiatives and cloud/software momentum.
- executiveFred Lowery
CEO who discussed the integrated 'One Schein' approach and Dentrix Ascend customer profitability improvements.
- executiveRon South
CFO who highlighted margin expansion drivers and timing of value-creation realization, including a non-recurring remeasurement gain headwind.
